* Mechanism of Action
CANCIDAS is a sterile, lyophilized product for intravenous (IV) infusion that contains a semisynthetic lipopeptide (echinocandin) compound synthesized from a fermentation product of Glarea lozoyensis. CANCIDAS is an echinocandin that inhibits the synthesis of Beta (1,3)-D-glucan, an integral component of the fungal cell wall.
CANCIDAS® is indicated in adults and pediatric patients (3 months and older) for:
– Empirical therapy for presumed fungal infections in febrile, neutropenic patients
– Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida.
– Treatment of esophageal candidiasis [see Clinical Studies]
– Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (e.g., amphotericin B, lipid formulations of amphotericin B, itraconazole). CANCIDAS has not been studied as initial therapy for invasive aspergillosis.